Information Provided By: 
Fly News Breaks for August 11, 2015
KPTI
Aug 11, 2015 | 08:07 EDT
Leerink analyst Michael Schmidt views the selloff yesterday in shares of Karyopharm Therapeutics as a buying opportunity. Sepsis is not an uncommon complication seen in patients with acute myeloid leukemia, and observations were limited to selinexor trials in AML and not other indications, Schmidt tells investors in a research note. He lowered his price target for shares to $41 from $58 and keeps an Outperform rating on the name. Karyopharm closed yesterday down $8.61 to $13.44.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
